Precision Scientific and BioMap Announce Strategic Collaboration to Build a Biological Computing Ecosystem Empowering Multi-Omics Research in Oncology

This collaboration will leverage the respective strengths of both parties to empower China’s top clinical oncology experts and provide insights for innovative drug research and development. The two parties plan to make long-term investments and conduct continuous research in specialized fields such as gynecologic, pancreatic, and prostate cancers. By developing advanced technologies, accumulating samples and massive multi-omics data, and enhancing data reusability, they aim to advance multi-omics research in oncology.

In connection with this collaboration, Precision Scientific will leverage its independently developedAIBERT®: An AI-Powered Big Data Mining Platform for Tumor Multi-Omics（AI-driven Big data analytics for Effective Response of cancer Therapy），Multidimensional integrated analysis of genomic, functional genomic, and pharmacogenomic data using deep learning algorithms to support precision medicine and the translational development of innovative drugs.In recent years, Precision Scientific has collaborated with multiple top-tier pharmaceutical companies, fully demonstrating the company’s “data-driven R&D” philosophy and showcasing the value that AIBERT can deliver to its pharmaceutical partners.

BioMap will leverage its independently developedBioMap HOPE Multi-Omics Intelligent Platform（Human Omics Precision Ecosystem），Providing world-leading, cutting-edge omics services to clinical oncology experts, the platform leverages a self-developed high-performance bio-computing engine to significantly enhance the mining efficiency of massive, multi-axial, heterogeneous biological data.By leveraging in-house R&D and ecosystem partnerships, we integrate a variety of cutting-edge advanced omics technologies to provide users with multi-omics services characterized by “underlying technology agnosticism,” “intelligent analysis,” and “multi-omics integration.” This empowers clinical experts to efficiently gain insights at the single-cell level and across multiple dimensions, including spatial transcriptomics and epigenomics, significantly accelerating the process of enabling clinical practice with frontier omics technologies.

In addition to providing its capability platform, BioMap will establish a special fund within its newly launched RMB 1 billion Multi-Omics Research Excellence Grant Program to provide financial support and free technical services for the clinical projects undertaken in collaboration with both parties., to further increase investment in research projects, expand the sample size and data dimensions of the projects, and facilitate the translation of research findings into practical applications.

Notably, this strategic partnership marks a significant step forward in the collaboration between the two parties on large-scale multi-omics data mining, following Precision Scientific’s receipt of Series A+ investment in Q3 2020 from BioMap’s predecessor, the Baidu Ventures Biomedical Investment Team. Currently, Precision Scientific has established long-term collaborations with dozens of large, R&D-focused pharmaceutical companies both in China and abroad. Leveraging its independently developed omics data mining system, AIBERT, the company provides decision support for new drug development. Building on this foundation, Precision Scientific offers end-to-end, one-stop services to pharmaceutical partners, covering exploratory research, central laboratory services, companion diagnostic development, and “diagnostic/therapeutic synergy,” thereby efficiently empowering its collaborative partners. The company’s technological strengths also extend to advantages in clinical precision testing products. It has launched multiple products in the Chinese market to support the practice of clinical precision medicine, covering more than 100 Grade IIIA hospitals nationwide and achieving hospital formulary inclusion and sales at top-tier institutions such as West China Hospital.

BioMap is China’s first biocomputing-driven life sciences platform company, founded by Robin Li, the founder of Baidu. Committed to long-term, large-scale investment, BioMap leverages the integrated innovation of advanced AI technologies and cutting-edge biotechnology to build novel multi-omics detection and analysis platforms, high-throughput experimental simulation systems, and intelligent molecular discovery engines. These efforts aim to accelerate the development of innovative drugs and diagnostic products, ultimately benefiting human health.

BioMap is committed to building a world-class multi-omics ecosystem. By combining in-house R&D with global investments, and partnering with diverse cutting-edge technologies and expert teams both domestically and internationally, BioMap jointly promotes multi-level, multi-dimensional, and longitudinal analysis of large clinical cohorts. This effort facilitates the elucidation of metabolic patterns in cancer, autoimmune diseases, and aging-related conditions, as well as the discovery of novel biomarkers and therapeutic targets, thereby accelerating the development of more innovative drugs and diagnostic products. To date, BioMap has invested in or collaborated with over 50 early-stage technology companies and research teams worldwide. Furthermore, BioMap will launch the “Multi-Omics Research Excellence Program,” backed by a RMB 1 billion investment, to empower partners such as universities, clinical research institutions, frontier omics enterprises, and innovative pharmaceutical companies. Leveraging financial support and the technical capabilities of the BioMap Multi-Omics Intelligent Platform, this program aims to conduct joint research on highly innovative biomedical questions with significant clinical value and accelerate the translation of research outcomes into practical applications.

Precision Scientific is a translational oncology company distinguished by its "data-driven" approach. The company possesses unique and leading technologies in multi-omics (including genomics), bioinformatics, and biostatistics/machine learning. Precision Scientific provides translational medicine services based on omics data to pharmaceutical companies, offering decision support for new drug development. It maintains central laboratory testing capabilities serving new drug R&D and collaborates with pharmaceutical firms to advance the development of companion diagnostic products. With unique technical capabilities in China, the company facilitates critical decisions throughout the drug development process, including target validation, biomarker research, indication selection, resistance mechanism studies, and exploration of combination therapy regimens. Precision Scientific boasts a high-caliber team with both technical and managerial expertise. Its core members hail from prestigious domestic and international research institutions, multinational pharmaceutical companies, and top-tier investment banks, including MD Anderson Cancer Center, Peking University, the Chinese Academy of Sciences, Labcorp, Abbott, and Roche.

The company operates internationally standardized central laboratories in Beijing and Suzhou. The Beijing laboratory, with a total area of 2,000 square meters, features mature high-throughput sequencing, molecular biology, and pathology platforms, offering comprehensive testing services including NGS, PCR, and immunohistochemistry. The Suzhou Central Laboratory, covering 1,000 square meters, is a multi-omics facility at the forefront of domestic capabilities, equipped for NGS, single-cell sequencing, gene expression profiling (Nanostring), and mass spectrometry-based proteomics.